# Estuary launches with $93 million Series A for kidney gene therapies

_Published Friday, October 16, 2026 at 9:18 AM EDT · Capital · Latest · Tier 2 — Notable_

![Estuary launches with $93 million Series A for kidney gene therapies — Primary](https://imgproxy.divecdn.com/2gOVd7kOG89-__i9vLYv2HnzngQH4FwX41aiL1P5Ccw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTQ2MDE0MzA1LmpwZw==.webp)

Estuary Biotherapeutics launched Friday with a $93 million Series A led by RA Capital Management to develop gene therapies for autosomal dominant polycystic kidney disease, BioPharma Dive reported. Investors included Alphabet's GV and Biogen's early-stage investment arm.

Its two lead programs aim to restore polycystins, proteins whose disruption causes kidney-damaging cysts. EST-201 would deliver a functional PKD2 gene, while EST-101 would supply useful portions of the protein produced by PKD1. Estuary expects human testing in 2027 and 2028, respectively. The proposed one-time treatments would be administered locally; delivering the genetic material to the kidneys remains a central development challenge.

## Sources

- [BioPharma Dive](https://www.biopharmadive.com/news/estuary-kidney-disease-gene-therapy-launch-emerged-biogen-biotech-startup/833114/)

---
Canonical: https://techandbusiness.org/newswire/bFxVFnBtbIGpXhPuUd-ZUW
Published: 2026-10-16T13:18:11.613Z
Story chronology: 2026-10-16T10:30:00.000Z
Retrieved: 2026-10-17T08:14:04.966Z
Publisher: Tech & Business (techandbusiness.org)